在CAR-T细胞疗法中对二次原发性恶性瘤和抗生素相互作用的药监测分析
Yun Peng1,2, Yuxuan Song1,2, Jiaxing Lin1,2
1Department of Urology, Peking University People's Hospital, Beijing, China.
Therapeutic advances in drug safety
|June 9, 2025
概括
抗生素对CAR-T细胞治疗患者的二次原发性恶性瘤 (SPM) 风险和时间的影响. 这种关联因CAR-T类型而异,有些人显示SPM风险降低,有些人显示风险增加和早期发病.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 免疫治疗是一种免疫疗法.
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法为癌症治疗提供了显著的进展.
- 二次性原发性恶性瘤 (SPMs) 在CAR-T患者中越来越令人担忧.
- 抗生素在CAR-T相关的SPM风险中的作用尚不清楚.
研究的目的:
- 系统地评估抗生素使用与接受CAR-T治疗的患者中SPM的发生率和时间之间的关联.
- 分析来自FDA的不良事件报告系统 (FAERS) 对CAR-T相关的SPM的数据.
主要方法:
- 分析FAERS数据从2017年第二季度到2024年第一季度.
- 信号分析,以探索不同CAR-T产品的抗生素和特定的SPM之间的关联.
- 累积危险曲线用于评估使用或不使用抗生素的SPM发病时间.
主要成果:
- 抗生素与SPM风险的关联因CAR-T治疗类型而异.
- 抗CD19的CAR-T疗法 (例如,brexucabtagene autoleucel) 显示抗生素降低了SPM风险.
- 抗BCMA疗法 (例如,idecabtagene vicleucel) 显示抗生素增加了SPM风险.
- 抗生素与CAR-T疗法中SPM早期发病有关.
结论:
- 抗生素与CAR-T治疗患者中SPM的风险和时间有关.
- 需要进一步的研究来了解抗生素和CAR-T疗法之间的复杂相互作用.
- 这些发现对临床管理和患者护理有潜在的影响.
更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
08:09Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
Published on: March 14, 2025
788
相关概念视频
01:19Pharmacovigilance
784
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
784
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489